EP1032394A1 - Utilisation de composes 11-phenyl-dibenzazepine substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferation cellulaire anormale et par la diarrhee chez l'homme et l'animal - Google Patents

Utilisation de composes 11-phenyl-dibenzazepine substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferation cellulaire anormale et par la diarrhee chez l'homme et l'animal

Info

Publication number
EP1032394A1
EP1032394A1 EP98960380A EP98960380A EP1032394A1 EP 1032394 A1 EP1032394 A1 EP 1032394A1 EP 98960380 A EP98960380 A EP 98960380A EP 98960380 A EP98960380 A EP 98960380A EP 1032394 A1 EP1032394 A1 EP 1032394A1
Authority
EP
European Patent Office
Prior art keywords
group
aryl
compounds
halogen
trihalomethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98960380A
Other languages
German (de)
English (en)
Inventor
Carlo Brugnara
Jose Halperin
Emile M. Bellot, Jr.
Mark Froimowitz
Richard John Lombardy
John J. Clifford
Ying-Duo Gao
Reem M. Haidar
Eugne W. Kelleher
Falguni M. Kher
Adel M. Moussa
Yesh P. Sachdeva
Minghua Sun
Heather N. Taft
Wayne I. Lencer
Seth Alper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Childrens Medical Center Corp
Original Assignee
Harvard College
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/159,333 external-priority patent/US6291449B1/en
Priority claimed from US09/159,337 external-priority patent/US20030134842A1/en
Application filed by Harvard College, Childrens Medical Center Corp filed Critical Harvard College
Publication of EP1032394A1 publication Critical patent/EP1032394A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La présente invention porte sur des composés 11-phényl-dibenzazépine substitués, et sur leurs analogues, qui sont des inhibiteurs spécifiques, puissants et sûrs des vannes à potassium activées par Ca2+ (canal Gardos) des hématies, de la prolifération cellulaire mammalienne et/ou de la sécrétion de chlorure électrogénique transépithélial stimulée par le sécrétagogue dans les cellules intestinales. Ces composés peuvent être utilisés pour réduire la déshydratation drépanocytaire et/ou retarder l'apparition de la falciformation ou déformation des hématies in situ dans des méthodes thérapeutiques utilisées dans le traitement ou la prévention de la drépanocytose. Ces composés peuvent être également utilisés pour inhiber la prolifération des cellules mammaliennes in situ dans des méthodes thérapeutiques utilisées dans le traitement ou la prévention de maladies caractérisées par une prolifération cellulaire anormale, ainsi que pour inhiber la sécrétion de chlorure dans les cellules intestinales dans des méthodes thérapeutiques utilisées dans le traitement de la diarrhée chez l'homme et l'animal.
EP98960380A 1997-11-20 1998-11-20 Utilisation de composes 11-phenyl-dibenzazepine substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferation cellulaire anormale et par la diarrhee chez l'homme et l'animal Withdrawn EP1032394A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US159333 1993-11-29
US97559497A 1997-11-20 1997-11-20
US975594 1997-11-20
US09/159,333 US6291449B1 (en) 1998-09-23 1998-09-23 Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours
US09/159,337 US20030134842A1 (en) 1997-11-20 1998-09-23 Methods for the treatment or prevention of inflammatory diseases characterized by abnormal cell proliferation
US159337 1998-09-23
PCT/US1998/024967 WO1999026628A1 (fr) 1997-11-20 1998-11-20 Utilisation de composes 11-phenyl-dibenzazepine substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferation cellulaire anormale et par la diarrhee chez l'homme et l'animal

Publications (1)

Publication Number Publication Date
EP1032394A1 true EP1032394A1 (fr) 2000-09-06

Family

ID=27388303

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98960380A Withdrawn EP1032394A1 (fr) 1997-11-20 1998-11-20 Utilisation de composes 11-phenyl-dibenzazepine substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferation cellulaire anormale et par la diarrhee chez l'homme et l'animal

Country Status (6)

Country Link
EP (1) EP1032394A1 (fr)
JP (1) JP2001523720A (fr)
AU (1) AU1598799A (fr)
CA (1) CA2310773A1 (fr)
IL (1) IL136209A0 (fr)
WO (1) WO1999026628A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291449B1 (en) 1998-09-23 2001-09-18 Children's Medical Center Corporation Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours
KR20040106298A (ko) * 2002-03-21 2004-12-17 아나디스 리미티드 불안정한 생활성 물질 및 포유동물 초유를 포함한 조성물,제조 및 치료 방법
AU2003212098B2 (en) * 2002-03-21 2008-07-24 Anadis Ltd Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
CN116847838A (zh) 2020-12-11 2023-10-03 桑昆专利有限公司 炎症性贫血的治疗和预防

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273992A (en) * 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
EP0781128B1 (fr) * 1994-09-16 2005-11-23 Children's Medical Center Corporation Metabolites de clotrimazole contre la drepanocytose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9926628A1 *

Also Published As

Publication number Publication date
AU1598799A (en) 1999-06-15
JP2001523720A (ja) 2001-11-27
CA2310773A1 (fr) 1999-06-03
IL136209A0 (en) 2001-05-20
WO1999026628A1 (fr) 1999-06-03

Similar Documents

Publication Publication Date Title
US6331564B1 (en) Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease
US6495567B1 (en) Triaryl methane compounds and their use in the treatment of diarrhea and scours
US6028103A (en) Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation
JP2008201783A (ja) 鎌状赤血球症のためのトリアリールメタン化合物
WO1999026628A1 (fr) Utilisation de composes 11-phenyl-dibenzazepine substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferation cellulaire anormale et par la diarrhee chez l'homme et l'animal
WO1999026624A1 (fr) Utilisation de composes de diphenyle indanone, indane et indole substitues dans le traitement ou la prevention de la drepanocytose, des maladies inflammatoires caracterisees par une proliferation cellulaire anormale et par la diarrhee chez l'homme et l'animal
US6534497B1 (en) Substitute 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
US6800658B2 (en) Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
US20020128256A1 (en) Methods for the treatment or prevention of inflammatory diseases characterized by abnormal cell proliferation
US20030134842A1 (en) Methods for the treatment or prevention of inflammatory diseases characterized by abnormal cell proliferation
US6291449B1 (en) Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours
AU2448399A (en) Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
US6992079B2 (en) Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
US20020004519A1 (en) Method for reducing chloride secetion by intestinal epithlial cells in situ
AU2640201A (en) Triaryl and diaryl compounds, their analogues and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000616

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI LU NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HAIDAR, REEM, M.

Inventor name: GAO, YING-DUO

Inventor name: CLIFFORD, JOHN, J.

Inventor name: LOMBARDY, RICHARD, JOHN

Inventor name: FROIMOWITZ, MARK

Inventor name: BELLOT, EMILE, M., JR.

Inventor name: HALPERIN, JOSE

Inventor name: BRUGNARA, CARLO

17Q First examination report despatched

Effective date: 20010521

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011201